CABA-201 Clinical Data from RESET-Myositis™, RESET-SLE™ and RESET-SSc™ Trials Presented at ACR Convergence 2024 Investor Call :: Cabaletta Bio, Inc. (CABA)

Contact

Our RESET^TM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.

CABA-201 Clinical Data from RESET-Myositis™, RESET-SLE™ and RESET-SSc™ Trials Presented at ACR Convergence 2024 Investor Call

Webcast